Latest European Expansion News

Redivium Limited advances its recapitalisation efforts and project development despite ASX suspension, withdrawing its European Green Bond and exploring new UK site options.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

DTI Group Ltd reported a 33% revenue increase to $5.69 million for the half-year ending December 2025, significantly narrowing its net loss while winning major contracts with Rio Tinto and CAF. The company’s strategic re-entry into Europe and a robust $175 million opportunity pipeline signal a promising outlook.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

International Graphite Limited has reported pilot-scale testwork results exceeding purity targets for expandable graphite, underpinning plans for a European production facility.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

Electro Optic Systems (EOS) addresses rumours about relocating its headquarters and stock listing to Europe, affirming no such decisions have been made despite strong growth in European defence markets.

International Graphite Limited has secured key approvals and funding to progress its Collie Micronising Facility and European Expandable Graphite Project, positioning itself as a major supplier outside China.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.